Letrozole is typically taken as a once-daily oral tablet for five consecutive days early in the menstrual cycle, starting on either cycle day 3 or cycle day 5. The standard starting dose is 2.5 mg, though your doctor may increase it to 5 mg or 7.5 mg if you don’t respond. While letrozole was originally developed as a breast cancer drug, it has become one of the most widely used fertility medications, and the specifics of when you start it, how much you take, and what happens in the days after you finish the course all affect how well it works.
How Letrozole Helps You Ovulate
Letrozole is an aromatase inhibitor, meaning it temporarily blocks the enzyme your body uses to produce estrogen.1PubMed Central. Letrozole for Female Infertility When estrogen drops, your brain reads the low level as a signal to ramp up follicle-stimulating hormone (FSH). That surge of FSH pushes the ovaries to develop a mature follicle, and ideally just one, which then releases an egg. The drug clears your system quickly, so by the time a follicle is maturing and estrogen levels begin climbing again, letrozole is no longer suppressing production. This short window of action is a key part of why the drug tends to produce single follicles rather than multiples.
Standard Dosing and the Five-Day Course
The most common starting protocol is 2.5 mg taken once a day for five days. You swallow the pill at roughly the same time each day, with or without food. If you respond to this dose, meaning an ultrasound shows a mature follicle developing, your doctor will likely keep you at 2.5 mg in future cycles. If not, the dose goes up.
In a study of women with PCOS who didn’t respond to the older drug clomiphene, follicle development occurred in about 23% of cycles at 2.5 mg, jumped to roughly 42% at 5 mg, and reached around 85% at 7.5 mg.2PubMed Central. Dosage Optimization for Letrozole Treatment in Clomiphene-Resistant Patients with Polycystic Ovary Syndrome: A Prospective Interventional Study A separate dose-escalation study found that about a third of women ovulated on 2.5 mg, roughly 63% of those who hadn’t responded then ovulated on 5 mg, and close to 79% of the remaining non-responders ovulated on 7.5 mg.3PubMed Central. Prevalence of Polycystic Ovarian Syndrome, Phenotypes and their Ovulation Response to Sequential Letrozole Dose Escalation among Infertile Women at a Tertiary Care Centre in Southern India The pattern is consistent: if the starting dose doesn’t get the job done, stepping up usually does. Most clinics will try up to three cycles of escalating doses before moving on to other options.
Cycle Day 3 or Cycle Day 5
One of the first things you’ll want to know is exactly when in your cycle to pop the first pill. Both day 3 and day 5 are widely used, and different clinics have strong preferences. A study comparing the two start days in women with PCOS found that starting on day 5 produced a higher conception rate per patient, about 76% compared with 65% in the day-3 group. Per-cycle ovulation rates were also higher in the day-5 group. However, live birth rates did not differ significantly between the two groups.4PubMed Central. Effect of different timing of letrozole initiation on pregnancy outcome in polycystic ovary syndrome
In practice, your doctor’s choice often depends on your specific situation. A day-3 start gives slightly more time for follicle recruitment, which can help women who tend to respond slowly. A day-5 start may produce a more dominant single follicle. Either way, “cycle day 1” is defined as the first day of full menstrual flow, not spotting, so you count forward from there.
Monitoring and Knowing When to Trigger
After you finish the five-day course, your clinic will typically schedule an ultrasound around cycle day 10 to 12 to measure follicle growth and endometrial thickness. Monitoring isn’t strictly required for every patient on letrozole, but it’s strongly advisable for determining stimulation response, timing an hCG trigger shot, and scheduling intercourse or insemination.
The ideal follicle size at the time of trigger has been studied, and the findings are more nuanced than a single magic number. One large study of letrozole-IUI cycles found that the best clinical pregnancy rates occurred when the dominant follicle measured between about 19 and 21 mm on the day of hCG trigger.5PubMed Central. Effect of follicle size on pregnancy outcomes in patients undergoing first letrozole-intrauterine insemination However, another study in cycles combining letrozole with gonadotropins reported the highest pregnancy rates when trigger happened at a smaller follicle size, between roughly 16 and 18 mm.6Reproductive BioMedicine Online. Optimal lead follicle size in letrozole human menopausal gonadotrophin intrauterine insemination cycles with and without spontaneous LH surge The difference likely comes down to whether gonadotropins are also in the mix and whether you’re surging on your own. Your clinic will use ultrasound measurements along with bloodwork to decide when the timing is right.
If you’re doing timed intercourse rather than IUI, the usual advice is to have sex the day of your trigger shot and the following day, since ovulation generally occurs about 36 hours after the injection.
Why Letrozole Instead of Clomiphene
For decades, clomiphene citrate was the default first-line ovulation induction drug. Letrozole has overtaken it in many clinical settings, and the data explain why. A landmark trial of nearly 750 women with PCOS found that letrozole produced a cumulative live birth rate of about 28%, compared with 19% for clomiphene, a statistically significant difference.7PubMed Central. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome A meta-analysis of nine randomized trials confirmed higher ovulation, pregnancy, and live birth rates with letrozole across the board.8PubMed. Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials
One of letrozole’s practical advantages is what it does to your uterine lining. Clomiphene has anti-estrogen effects on the endometrium, which can thin it out and potentially reduce receptivity. Letrozole doesn’t carry that baggage. A meta-analysis found that endometrial thickness was significantly greater in letrozole cycles than clomiphene cycles.9PubMed. Comparison of Letrozole and Clomiphene Citrate in Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis In women who had previously had poor endometrial response on clomiphene, switching to letrozole improved midcycle endometrial thickness from about 5.7 mm to about 9 mm and restored a healthy multilayered endometrial pattern in the vast majority of cases.10Middle East Fertility Society Journal. Impact of letrozole on ultrasonographic markers of endometrial receptivity in polycystic ovary syndrome women with poor endometrial response to clomiphene citrate despite adequate ovulation If your doctor has noted a thin lining on clomiphene, the switch to letrozole often solves that problem on its own.
Multiple Pregnancy Risk
One of the fears with any ovulation-induction drug is the chance of twins or higher-order multiples. Letrozole’s tendency to produce a single dominant follicle makes this less of an issue than with other treatments. A meta-analysis found that the multiple pregnancy rate was significantly lower with letrozole compared to clomiphene.11PubMed Central. Comparative Outcomes of Letrozole Versus Clomiphene Citrate for Ovulation Induction in Patients With PCOS: Systematic Review and Meta-Analysis In one trial of women with unexplained infertility, the twin rate on letrozole was about 13% of ongoing pregnancies, comparable to clomiphene’s 9%, and substantially lower than the 32% rate seen with gonadotropin injections.12PubMed Central. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility All multiples in the letrozole group were twins, with no triplets, whereas gonadotropin use produced both twins and triplets in that study.
The low multiple rate is also one reason monitoring is considered less urgent with letrozole than with injectable medications. Still, if ultrasound reveals three or four mature follicles, your doctor will likely recommend canceling the cycle or converting to IVF rather than proceeding with intercourse or IUI.
Extended and Staggered Regimens
Not everyone responds to the standard five-day course, even at higher doses. For those women, some clinics use an extended protocol: the same 2.5 mg dose spread over 10 days instead of five. A randomized controlled trial comparing the two approaches found that 85% of women on the 10-day regimen developed follicles in their first cycle, versus about 53% on the five-day regimen. Fewer women in the extended group needed dose escalation, and none required gonadotropin injections, compared with about 16% in the standard group. Pregnancy rates per patient were similar, around 33 to 35%, suggesting the extended regimen mainly helps women avoid the costs and complexity of stepping up to stronger medications.13PubMed Central. Efficacy of an Extended 10-day Letrozole Regimen Compared to the 5-day Regimen in Enhancing Ovulation in Infertile Women with Polycystic Ovary Syndrome: A Randomised Controlled Trial
Another approach is a two-step protocol for women who resist standard letrozole. In one study, women first tried a 7-day course; those who didn’t ovulate then received a 10-day course in the next cycle. Combining both steps, the cumulative ovulation rate reached about 93%, with a cumulative live birth rate near 25%.14Fertility and Sterility. Efficacy of a 2-step extended letrozole protocol in women with polycystic ovary syndrome and letrozole resistance These extended regimens aren’t standard everywhere, but they offer an option before jumping to injectable gonadotropins.
Luteal Phase Support
After ovulation, the second half of your cycle (the luteal phase) needs adequate progesterone to sustain a pregnancy. Whether you need supplemental progesterone after a letrozole cycle is debated, and the evidence is genuinely mixed.
A retrospective study of nearly 500 letrozole cycles found no significant difference in clinical pregnancy rates between women who received vaginal progesterone after ovulation and those who didn’t.15Reproductive BioMedicine Online. Luteal phase support with progesterone does not improve pregnancy rates in patients undergoing ovarian stimulation with letrozole But a more recent matched study of over 1,100 letrozole-IUI cycles told a different story: women who received luteal phase support had a live birth rate of about 20%, compared with roughly 15% in the control group, a statistically significant improvement.16PubMed. Luteal phase support with oral progesterone improves live birth rate in intrauterine insemination cycles using letrozole An earlier study specifically in PCOS patients found a particularly striking difference, with clinical pregnancies in about 21% of letrozole cycles using progesterone versus none in the cycles without it, though the sample was small.17Fertility and Sterility. Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation induction
Given this uneven evidence, many reproductive endocrinologists prescribe luteal progesterone as a low-risk addition. When used, it’s typically started two days after ovulation or insemination and continued until a pregnancy test, then extended through the first trimester if the test is positive. Both vaginal micronized progesterone and oral formulations are used.
Adding Metformin
If you have PCOS, you may be wondering whether taking metformin alongside letrozole adds any benefit. The research here is surprisingly mixed. One study found that adding metformin raised the clinical pregnancy rate from about 19% to 33% per cycle, a significant improvement, though the benefit appeared to be concentrated in women with a BMI under 30.18Fertility and Sterility. Impact of metformin combined with letrozole for ovulation induction in patients with polycystic ovarian syndrome However, two other randomized trials found that adding metformin did not produce statistically significant improvements in ovulation or pregnancy rates.19Italian Journal of Gynæcology & Obstetrics. Comparative efficacy of letrozole versus letrozole-metformin in the ovulation and clinical pregnancy rate in polycystic ovary syndrome: a prospective randomized controlled study 20Pyramid Journal of Medicine. Letrozole and metformin versus letrozole alone for ovulation induction in women with polycystic ovarian syndrome: a randomised controlled trial
The takeaway is that metformin isn’t a universal booster for letrozole, but it may help a subset of patients, particularly those who are not obese and have insulin resistance as a prominent feature of their PCOS. If you’re already taking metformin for metabolic reasons, continuing it during letrozole treatment is reasonable; starting it specifically to improve letrozole outcomes is a conversation worth having with your doctor, but don’t expect dramatic changes.
Safety and Birth Defect Concerns
If you’ve done your own research, you may have come across warnings about letrozole and birth defects. This concern traces back to a single conference abstract from 2005 that reported higher malformation rates among letrozole-conceived babies. The finding alarmed the drug manufacturer, and the label still carries a strong warning against use in pregnancy. But more than a decade of subsequent research has not supported that initial alarm.
A systematic review and meta-analysis pooling data from thousands of letrozole-conceived babies found an overall congenital malformation rate of about 2.2%, with no significant increase compared to clomiphene, natural conception, or other fertility agents.21Human Reproduction Update. Risk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis A study comparing letrozole-conceived babies with those from natural conception found malformation rates of 2.5% and 2.9% respectively, with no statistical difference.22PubMed Central. Congenital Malformations among Babies Born Following Letrozole or Clomiphene for Infertility Treatment A separate analysis of IVF and assisted reproduction cycles reached the same conclusion: no increased risk of major congenital anomalies in letrozole cycles compared with natural cycles.23Human Reproduction. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology
Letrozole is used off-label for fertility. Its approved indication is post-menopausal breast cancer, which is why the packaging doesn’t mention ovulation induction. Off-label doesn’t mean unsupported or unsafe; it means the manufacturer hasn’t pursued a regulatory approval specifically for fertility use. The drug clears the body well before implantation would occur, which is part of why safety data have been reassuring. Still, you should never take letrozole if there’s any chance you’re already pregnant, and a baseline ultrasound before starting a new cycle helps rule that out.
Which Fertility Diagnoses Benefit Most
Letrozole’s strongest evidence base is in PCOS. The improvements in ovulation rate, pregnancy rate, and live birth rate compared to clomiphene are well-documented across multiple large trials and meta-analyses. For unexplained infertility, the picture is more nuanced. A scoping review found that pregnancy rates were higher with letrozole-only protocols than with some combination regimens in the unexplained infertility group, suggesting the drug is useful there too.24PubMed Central. Scoping Review of Letrozole in Assisted Reproductive Cycles: Efficacy and Outcomes Across Infertility Causes It is also used in IVF stimulation protocols, particularly in patients at risk of ovarian hyperstimulation, though the dosing and goals differ significantly from simple ovulation induction.
The Cost Advantage
One underappreciated reason letrozole has become so popular is the price. As a generic oral medication, it costs a fraction of what injectable gonadotropins run. A cost-effectiveness analysis comparing letrozole and clomiphene for PCOS found that letrozole dominated on a cost-per-live-birth basis, driven primarily by its higher pregnancy rate rather than any difference in drug price.25Fertility and Sterility. To compare the cost effectiveness of Letrozole to Clomiphene for treatment of anovulatory infertility related to the Polycystic Ovary Syndrome For unexplained infertility, an economic analysis found that letrozole offered the best value for money across a broad range of willingness-to-pay thresholds, compared to both clomiphene and gonadotropins.26Human Reproduction. Cost-effectiveness of ovarian stimulation agents for IUI in couples with unexplained subfertility For many patients, this means being able to pursue several medicated cycles before needing to consider the more expensive step of injectable medications or IVF.
Common Side Effects and What to Expect Day to Day
Because letrozole temporarily suppresses estrogen, you may notice mild menopausal-type symptoms during the five days you take it and shortly after. Hot flashes, headaches, and fatigue are the most commonly reported. Some women feel mildly bloated or moody. These symptoms typically resolve within a few days of finishing the course, as the drug clears your system quickly, well before ovulation occurs. Compared to clomiphene, letrozole tends to cause fewer visual disturbances and less of the emotional volatility that some women find debilitating on clomiphene.
One practical tip: letrozole is taken once daily, and the timing within the day doesn’t matter much. Many women take it at bedtime so that any headache or dizziness happens during sleep. If you miss a dose, take it as soon as you remember the same day, but don’t double up. A single missed pill in a five-day course is unlikely to derail the cycle entirely, though it’s worth mentioning to your clinic.
Ovulation after a letrozole course usually happens around cycle day 14 to 17, depending on your starting day and individual response. Some women ovulate earlier, especially at higher doses. This is why mid-cycle monitoring matters: if your follicle matures faster than expected and you rely on a calendar rather than an ultrasound, you could miss your window.